172: Insulin detemir in pregnancy: does it cross the placenta?
The objective of this study was to determine if IDet is present in the fetal circulation in pregnant woman treated with IDet. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - December 19, 2014 Category: OBGYN Authors: Katarzyna Suffecool, Barak Rosenn, Eric Niederkofler, Urban Kiernan, Janelle Foroutan, Gideon Koren Tags: Poster session I Source Type: research
649: A randomized controlled trial of insulin detemir versus insulin NPH for the treatment of pregnant women with gestational diabetes and type 2 diabetes
To determine if insulin Detemir (IDet) is non-inferior to insulin NPH for the treatment of gestational diabetes (GDM) and Type 2 diabetes in pregnancy (T2DM). (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - December 19, 2014 Category: OBGYN Authors: Kimberly Herrera, Barak Rosenn, Janelle Foroutan, Brianne Bimson, Zainab Al Ibraheemi, Lois Brustman Tags: Poster session IV Source Type: research
Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
CONCLUSION: Insulin initiation and intensification using IDet+IAsp was not inferior to BIAsp1-2-3 in insulin-naive patients with T2DM not controlled by OGLDs. Both regimens led to similar reductions in HbA1c values after 50 weeks of treatment.
PMID: 25483023 [PubMed - as supplied by publisher] (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 4, 2014 Category: Endocrinology Authors: Malek R, Ajili F, Assaad-Khalil SH, Shinde A, Chen JW, Van den Berg E Tags: Diabetes Metab Source Type: research
An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes
Journal of Medical Economics, Ahead of Print. (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 22, 2014 Category: Health Management Tags: article Source Type: research
Short-Term Cost-Effectiveness Analysis of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn (Nph) In Patients With Type 2 Diabetes Mellitus in Spain
To estimate the short-term cost-effectiveness of insulin detemir compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin treatment in patients with Type 2 Diabetes Mellitus (T2DM) in Spain. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: de Arellano A. Ramírez, C. Morales, Luis D. De, M.G. Ferrario, L. Lizán Source Type: research
Cost-Effectiveness Analysis of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn (Nph) In Patients With Type 1 Diabetes Mellitus In Spain
To estimate the short-term cost-effectiveness of insulin detemir compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin treatment in patients with Type 1 Diabetes Mellitus (T1DM) in Spain (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: de Arellano A. Ramírez, L. Lizán, M. Prades, C. Morales, Luis D. De Source Type: research
Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data
ConclusionsThis study showed contrasting results when patients with T2DM switch between basal insulin analogs, although these preliminary results may be subject to limitations in the analysis. Nevertheless, this study questions the therapeutic interchangeability of GLA and DET, and calls for further investigations. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - October 31, 2014 Category: Endocrinology Authors: P. Levin, W. Wei, R. Miao, F. Ye, L. Xie, O. Baser, J. Gill Tags: ORIGINAL ARTICLE Source Type: research
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina
Conclusions From a payer’s perspective in Argentina, cost savings related to the use of IG represented one third of total treatment costs. Sensitivity analyses confirmed the robustness of these results. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - October 12, 2014 Category: Global & Universal Source Type: research
Open Flow Microperfusion: Pharmacokinetics of human insulin and insulin detemir in the interstitial fluid of subcutaneous adipose tissue
ConclusionsBy using OFM we were able to monitor albumin bound insulin detemir directly in the interstitial fluid of subcutaneous tissue and confirm its delayed transendothelial passage to a peripheral site of action. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - September 19, 2014 Category: Endocrinology Authors: C. Höfferer, D. Tutkur, C. Fledelius, C. L. Brand, T. J. Alsted, J. Damgaard, E. Nishimura, C.B. Jeppesen, S. I. Mautner, T. R. Pieber, F. Sinner Tags: ORIGINAL ARTICLE Source Type: research
Weight‐neutral effect of once‐daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study
ConclusionsOnce‐daily insulin detemir as add‐on to OADs in Chinese patients with type 2 diabetes showed effective glycemic control and a low risk of hypoglycemia. Weight‐neutral effects were observed in different BMI subgroups. (Source: Journal of Diabetes)
Source: Journal of Diabetes - September 4, 2014 Category: Endocrinology Authors: Changyu Pan, Ping Han, Linong Ji, Qiuhe Ji, Juming Lu, Jing Lin, Jie Liu, Benli Su, Jingmei Shi, Penghua Wang Tags: Original Article Source Type: research
Long-Acting Insulin Analogues and Diabetic Retinopathy: A Retrospective Cohort Study.
Abstract
PURPOSE: Long-acting insulin analogues were developed to facilitate consistent glycemic control without excessive hypoglycemia. However, structural modifications of the insulin molecule can alter biological responses and binding characteristics with specific receptors. The aim of this study was to estimate the risk of sight-threatening diabetic retinopathy (STDR) associated with treatment using long-acting insulin analogues compared with intermediate-acting insulin in patients with type 2 diabetes mellitus (T2DM).
METHODS: A retrospective cohort consisting of patients with T2DM aged 20 yea...
Source: Clinical Therapeutics - July 28, 2014 Category: Drugs & Pharmacology Authors: Lin JC, Shau WY, Lai MS Tags: Clin Ther Source Type: research
Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study
Conclusions:
Initiation of basal insulin analogues, IDet and IGlar, were associated with clinically significant glycaemic improvements. A lower risk of minor hypoglycaemia and greater odds of weight loss >=1 kg was observed with IDet compared with IGlar.Trial registration: NCT00825643 and NCT00740519 (Source: BMC Endocrine Disorders)
Source: BMC Endocrine Disorders - July 21, 2014 Category: Endocrinology Authors: Taner DamciRifat EmralAnne Louise SvendsenTanzer BalkirJiten Vora Source Type: research
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes
Conclusion
A statistically significant association between NSHE and SHE frequency was found in T1DM and T2DM. These data provide a clear rationale for the reduction of hypoglycemic events, regardless of severity, while striving for optimal glycemic control. (Source: Diabetes Therapy)
Source: Diabetes Therapy - July 15, 2014 Category: Endocrinology Source Type: research
Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus
ConclusionInsulin detemir provides similar glycemic control with glargine, but, approximately 27% higher mean basal and 19% higher mean total insulin doses with two‐fold more twice‐daily basal insulin injection requirement. (Source: Pediatric Diabetes)
Source: Pediatric Diabetes - July 11, 2014 Category: Endocrinology Authors: Saygın Abalı, Serap Turan, Zeynep Atay, Tülay Güran, Belma Haliloğlu, Abdullah Bereket Tags: Original Article Source Type: research
Weight‐neutral effect of once‐daily insulin detemir in Chinese type 2 diabetes patients—subgroup analysis of the SOLVE study
ConclusionsOnce daily insulin detemir as add‐on to OADs in Chinese patients with type 2 diabetes showed effective glycemic control, low risk in hypoglycemia. Weight‐neutral effect was observed in different BMI subgroups. (Source: Journal of Diabetes)
Source: Journal of Diabetes - June 9, 2014 Category: Endocrinology Authors: Changyu Pan, Ping Han, Linong Ji, Qiuhe Ji, Juming Lu, Jing Lin, Jie Liu, Benli Su, Jingmei Shi, Penghua Wang Tags: Original Article Source Type: research
